PAVMed

Coming – November 10

Beyond the IV: Reinventing Vascular Access and Cancer Care

Date and Time

November 10

–

4:00 PM ET / 1:00 PM PT

Details will be shared with confirmed attendees

About this Event

How PAVmed is advancing innovative medical technologies designed to improve patient outcomes and reduce healthcare costs.

Some of healthcare’s greatest opportunities lie in rethinking procedures and practices that medicine has relied upon for decades.

PAVmed is advancing two innovative technologies that address fundamental challenges in patient care.

PortIO is developing the first implantable intraosseous vascular access device designed for long-term use, potentially transforming how medications and fluids are delivered to patients. Unlike conventional intravenous ports and catheters, PortIO accesses the body’s circulatory system through bone marrow, offering the potential for simpler, maintenance-free access with fewer complications. With its first-in-human study completed and published, PortIO is advancing toward its next regulatory and commercial milestones.

Veris Health is bringing continuous, personalized monitoring to cancer care. Its commercial-stage platform, already deployed at The Ohio State University, connects patients and clinicians between appointments, helping identify potential complications before they become medical emergencies. An implantable physiologic monitor in development could further expand the platform’s capabilities.

Together, these technologies illustrate PAVmed’s broader strategy of developing differentiated medical innovations through a shared infrastructure designed to accelerate development and commercialization.

Join us for a Fireside Chat with PAVmed leadership to explore PortIO’s clinical progress and market opportunity, Veris Health’s expanding oncology platform, and PAVmed’s vision for the future of patient care.

Sign Up Today

SHARE THIS EVENT

This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts and referenced statistics, contained in this presentation, including statements regarding future company strategy, operations, financial position, revenues, projected costs, plans and objectives of management, will be forward-looking statements.

All statements and expressions are the sole opinion of the company and are subject to change without notice. The Company is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial advisor, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. Information contained herein contains “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities and Exchange Act of 1934, as amended. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be “forward looking statements”. Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of words such as “expects”, “will”, “anticipates”, “estimates”, “believes”, or by statements indicating certain actions “may”, “could”, “should” or “might” occur.